Replies to post #224499 on Biotech Values

[biotech_researcher]

drug-resistant fungi and bacteria should become news of the decade as it plays out.

[biocqr]

Scynexis (SCYX) has the only commercial trial for Candida Auris on ClinicalTrials.gov. Interim data to be presented April 13...

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Candidiasis Caused by Candida Auris (CARES) (CARES)

https://clinicaltrials.gov/ct2/show/NCT03363841?cond=Candida+Auris&rank=1

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study

https://www.prnewswire.com/news-releases/scynexiss-ibrexafungerp-shows-favorable-clinical-activity-in-resistant-fungal-infections-including-candida-auris-cases-from-the-cares-study-in-data-to-be-presented-at-the-29th-eccmid-300823802.html

Six presentations will provide additional evidence of the potent and broad antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as promising preclinical data

Case studies from the CARES trial, the first study of an investigational agent to treat patients with Candida auris infections, show favorable outcomes following treatment with oral ibrexafungerp

[DewDiligence]

Re: Resistant fungi

I commented on this story—from the ag-biotech perspective—in:

The posited linkage between antifungal crop sprays &resistant fungi is tenuous,IMO. Still,this is yet another potentially ruinous issue for investors in ag-biotech companies—including the pending Corteva spin fm $DWDP. I will have to rethink my own plans in the ag-biotech sector.

— Roy Friedman (@DewDiligence) April 6, 2019

This could be a deal-breaker for prospective investments in the ag-biotech sector (such as the Corteva spin-off from DWDP).